Crossmark

Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study

Crossref DOI link: https://doi.org/10.1007/s00277-022-04887-8

Published Online: 2022-07-23

Published Print: 2022-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cella, David

Sarda, Sujata P.

Hsieh, Ray

Fishman, Jesse

Hakimi, Zalmai

Hoffman, Kate

Al-Adhami, Mohammed

Nazir, Jameel

Cutts, Katelyn

Lenderking, William R. https://orcid.org/0000-0002-3080-3643
Funding

Funding for this research was provided by:

Apellis Pharmaceuticals, Inc.
License Information

Text and Data Mining valid from 2022-07-23

Version of Record valid from 2022-07-23
More Information

Article History

Received: 10 November 2021

Accepted: 5 June 2022

First Online: 23 July 2022

Declarations

:

: DC reports consulting honoraria from Evidera and Apellis Pharmaceuticals, Inc., and ownership and role as President at. WRL, RH, and KC are current employees at Evidera. SS, JF, KH, and MA-A are current employees and equity holders of Apellis Pharmaceuticals, Inc. ZH and JN are current employees of Sobi.

Document is current

Any future updates will be listed below